


Solifenacin-d₅ succinate

Cat. No.:	HY-A0002S
Molecular Formula:	C ₂₇ H ₂₇ D ₅ N ₂ O ₆
Molecular Weight:	485.58
Target:	mAChR; Isotope-Labeled Compounds
Pathway:	GPCR/G Protein; Neuronal Signaling; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Solifenacin-d ₅ (succinate) is deuterium labeled Solifenacin (Succinate). Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pK _i s of 7.6, 6.9 and 8.0 for M ₁ , M ₂ and M ₃ receptors, respectively.		
IC₅₀ & Target	mAChR2	mAChR1	mAChR3
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. *Int J Clin Pract.* 2008 Nov;62(11):1675-83.
- [3]. Hoffstetter S, Leong FC. Solifenacin succinate for the treatment of overactive bladder. *Expert Opin Drug Metab Toxicol.* 2009 Mar;5(3):345-50.
- [4]. Imamura T, et al. Combined treatment with a β₃-adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats. *NeuroUrol Urodyn.* 2017 Apr;36(4):1026-1033.
- [5]. Krishna SR, Rao BM, Rao NS. A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography. *J Chromatogr Sci.* 2010 Nov;48(10):807-10.
- [6]. Ohtake A, Sato S, Sasamata M, Miyata K. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. *J Pharmacol Sci.* 2010;112(2):135-41. Epub 2010 Feb 4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA